

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement, for which the directors (the “Directors”) of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief:- (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People’s Republic of China)
(Stock code: 8329)

Continuing Negotiation on Proposed Acquisition

Reference is made to (1) the announcements of the Company dated 3 March 2009 and 23 April 2009, respectively, regarding, among other things, (i) the entering into of a non-legally binding letter of intent among the Company, 深圳市海王生物工程股份有限公司 (Shenzhen Neptunus Bio-engineering Company Limited*) and 深圳海王藥業有限公司 (Shenzhen Neptunus Pharmaceutical Company Limited*) (collectively the “Parties”) on 2 March 2009 in respect of the proposed acquisition of 80% of the equity interest in 福州海王福藥制藥有限公司 (Fuzhou Neptunus Fuyao Pharmaceutical Company Limited*) (the “Proposed Acquisition”) and the proposed disposal of the business and assets in relation to the production and sale of cytokines products by the Company (the “Proposed Disposal”); and (ii) the proposed entering into of a formal sale and purchase agreement for the Proposed Acquisition and the Proposed Disposal by the Parties between June and July 2009; (2) the announcement of the Company dated 27 August 2009, regarding the postponement of the negotiations on the Proposed Acquisition and the Proposed Disposal between the Parties. The board of Directors (the “Board”) of the Company announces that the

Parties have now decided to continue the negotiation on the Proposed Acquisition in this month. The Proposed Disposal will not be dealt with in the negotiation. Further announcement will be made by the Company if there is any further development on the Proposed Acquisition and/or the Proposed Disposal as and when appropriate.

BY ORDER OF THE BOARD
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Si Min
Chairman

Shenzhen, the PRC
11 May 2010

As at the date of this announcement, the executive Directors are Mr. Zhang Si Min and Mr. Chai Xiang Dong; the non-executive Directors are Ms. Yu Lin and Mr. Ren De Quan; and the independent non-executive Directors are Mr. Lu Sun, Mr. Yick Wing Fat, Simon and Mr. Poon Ka Yeung.

** for identification purpose only*